Role
10%+ Owner
Signature
Signed by managing member of Drugs Made In America Acquisition LLC /s/ Lynn Stockwell
Stock symbol
DMAA
Transactions as of
Jan 29, 2025
Transactions value $
$0
Form type
4
Date filed
2/4/2025, 07:41 PM
Previous filing
Jan 10, 2025
Next filing
Feb 18, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DMAA Ordinary shares Purchase +400K +4.06% 10.3M Jan 29, 2025 Direct F1
transaction DMAA Ordinary shares Other -400K -3.9% 9.86M Jan 29, 2025 Direct F2
transaction DMAA Ordinary shares Sale -5.7M -57.81% 4.16M Jan 29, 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAA Rights to receive ordinary shares Purchase +400K 400K Jan 29, 2025 Ordinary shares 400K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the 400,000 private units owned by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $4,000,000.
F2 As of the Transaction Date, the reporting person transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.
F3 As of the Transaction Date, pursuant to share transfer agreements, the reporting person transferred an aggregate of 5,698,363 ordinary shares for consideration ranging from no consideration to $1.50 per share.
F4 The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.